ClinicalTrials.gg
Not yet recruitingNCT07467590TRIUNITE-07Updated Mar 12, 2026

Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study

A Phase 2 interventional study of High- and Low-Dose Radiotherapy and Anti-Angiogenic TKI and Anti-PD-1 Therapy in Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming and Immune Response, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer. It will also evaluate long-term survival outcomes and explore potential biomarkers associated with tumor response and immune modulation.

The main questions it aims to answer are:

Does the high- and low-dose radiotherapy regimen followed by sequential anti-angiogenic TKI and anti-PD-1 therapy improve the objective response rate (ORR) in patients with advanced metastatic colorectal cancer?

What are the disease control rate (DCR) and survival outcomes following this treatment strategy?

Are tumor response and long-term survival associated with specific biomarkers related to systemic immune modulation induced by radiotherapy to different metastatic organs?

How does this radiotherapy pattern affect tumor immune infiltration in metastatic lesions?

This is a single-arm, single-center, prospective Phase II clinical study designed to evaluate the efficacy of a high- and low-dose radiotherapy regimen targeting metastatic lesions followed by sequential anti-angiogenic TKI and anti-PD-1 antibody therapy in patients with advanced metastatic colorectal cancer.

Participants will:

Receive high- and low-dose radiotherapy to metastatic lesions. Subsequently receive anti-angiogenic TKI combined with anti-PD-1 antibody therapy.

Undergo regular clinical assessments and imaging evaluations to determine tumor response.

Provide blood and tumor samples for biomarker and immune infiltration analysis. Be followed for survival outcomes and disease progression.

02

Conditions studied

  • Refractory Colorectal Cancer
  • Radiotherapy-Induced Immune Priming
  • Immune Response
03

In context

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's planned enrollment of 33 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is the lead sponsor of 121 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and willingness to sign a written form.
  2. Age 18-80 years, male or female.
  3. confirmed microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal adenocarcinoma.
  4. Clinical stage IV disease confirmed by systemic imaging. At least two measurable lesions per 1.1, including:

    At least one lesion ≥2 cm in diameter and at least one lesion \<2 cm in diameter;

    For lesions within the same organ, at least one lesion ≥2 cm and one lesion \<2 cm must be located within independent, non-overlapping radiation fields;

    For lesions in different organs, high-dose and low-dose radiotherapy should preferably be delivered to lesions in different organs.

    or later treatment setting, defined as disease progression after prior platinum- and irinotecan-based chemotherapy, including:

  5. Failure after first-line triplet chemotherapy containing platinum and irinotecan; Or failure after first-line platinum-based chemotherapy followed by second-line irinotecan-based chemotherapy.
  6. Ability to swallow oral medication.
  7. performance status 0-1.
  8. Adequate organ function as defined by laboratory criteria.

Exclusion criteria

Exclusion Criteria:

Diffuse miliary liver or lung , or bulky metastatic lesions ≥10 cm in diameter.

Presence of .

  1. History of severe to monoclonal antibodies or anti-angiogenic agents.
  2. Prior exposure to (including anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., targeting ICOS, 0, CD137, GITR, OX40), or any prior cancer immunotherapy.
  3. Active disease or history of autoimmune disease, including but not limited to interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (patients on stable hormone replacement therapy may be eligible). Patients with psoriasis or childhood asthma/allergy that has completely resolved and requires no adult intervention may be eligible; patients requiring bronchodilator therapy are excluded.
  4. History of immunodeficiency, including positive test, congenital or acquired immunodeficiency, prior organ transplantation, or bone marrow transplantation.
  5. Uncontrolled cardiovascular disease, including:

    class II or higher heart failure;

  6. Unstable angina;
  7. Myocardial infarction within 1 year;
  8. uncontrolled supraventricular or ventricular arrhythmias.
  9. Severe infection ( grade >2) within 4 weeks prior to first study treatment, including severe pneumonia, bacteremia, or infection requiring hospitalization. Active pulmonary inflammation on baseline imaging, signs or symptoms of infection within 14 days before treatment requiring systemic antibiotics (except prophylactic antibiotics), or active tuberculosis (current or within 1 year without adequate treatment).
  10. Active (HBV DNA ≥2000 IU/mL) or active (positive HCV antibody with detectable HCV RNA above the lower limit of detection).
  11. Diagnosis of another within 5 years prior to first study treatment, except for malignancies with low risk of metastasis or death (5-year survival rate >90%), such as adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
  12. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    High- and Low-Dose Radiotherapy Followed by Sequential Anti-Angiogenic TKI and Anti-PD-1 Therapy

    Radiation: High- and Low-Dose Radiotherapy · Drug: Anti-Angiogenic TKI and Anti-PD-1 Therapy

Interventions

  • RadiationHigh- and Low-Dose Radiotherapy

    Participants will receive a stratified high- and low-dose radiotherapy regimen to metastatic lesions based on lesion size, followed by sequential anti-angiogenic tyrosine kinase inhibitor (TKI) and anti-PD-1 antibody therapy. Metastatic lesions with a maximum diameter ≤2 cm will be treated with stereotactic body radiotherapy (SBRT) at 8 Gy per fraction for 3 consecutive fractions (total dose 24 Gy) prior to initiation of the first cycle of targeted and immunotherapy. The total cumulative volume of lesions treated with SBRT will not exceed 100 cm². Metastatic lesions with a maximum diameter \>2 cm will receive low-dose radiotherapy (LDRT) at 3 Gy per fraction for 5 fractions. LDRT will be administered rhythmically, with one fraction delivered prior to each cycle of targeted and immunotherapy, for a total of five fractions. The total cumulative volume of lesions treated with LDRT will not exceed 500 cm². Within 7 days after completion of radiotherapy, participants will initiate systemi

  • DrugAnti-Angiogenic TKI and Anti-PD-1 Therapy

    Participants will receive systemic therapy consisting of an oral anti-angiogenic tyrosine kinase inhibitor (TKI) in combination with an intravenous anti-PD-1 monoclonal antibody. The anti-angiogenic TKI will be administered orally according to the approved dosing schedule. The anti-PD-1 antibody will be administered intravenously at standard dosing intervals. Treatment will begin within 7 days after completion of radiotherapy and will continue until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision. Safety will be monitored throughout treatment, and adverse events will be graded according to CTCAE version 5.0.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Time frame: At the end of 2 treatment cycles (approximately 6-8 weeks after treatment initiation)

Secondary outcomes

  1. Disease Control Rate (DCR)

    Disease Control Rate is defined as the proportion of participants achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) according to RECIST version 1.1.

    Time frame: At the end of 2 treatment cycles (approximately 6-8 weeks after treatment initiation).

  2. Progression-Free Survival (PFS)

    Time frame: From the first radiotherapy treatment until disease progression or death, assessed up to 24 months

  3. Overall Survival (OS)

    Time frame: From the first radiotherapy treatment until death from any cause, assessed up to 24 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 12, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2029
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07467590
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Mar 12, 2026

Study contacts

Chuan Chen, Professor
Contact
cxq13396083059@163.com
18084012018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion